Nivalis Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in discovery, development, and commercialization of product for patients with cystic fibrosis. Its product includes N91115, a small molecule that addresses a defect in the cystic fibrosis transmembrane conductance regulator. The company was founded in 2008 and is headquartered in Boulder, CO.
Market Cap | 263.562 Million | Shares Outstanding | 30.294 Million | Avg 30-day Volume | 151.07 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.46 |
Price to Revenue | 8.0164 | Debt to Equity | 0.0594 | EBITDA | -45.265 Million |
Price to Book Value | 2.3521 | Operating Margin | -138.2633 | Enterprise Value | 59.54 Million |
Current Ratio | 2.583 | EPS Growth | -0.195 | Quick Ratio | 2.523 |
1 Yr BETA | 1.4308 | 52-week High/Low | 14.4 / 6.0 | Profit Margin | -139.4148 |
Operating Cash Flow Growth | -74.0749 | Altman Z-Score | 0.3719 | Free Cash Flow to Firm | 12.117 Million |
Earnings Report | 2022-08-09 |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
FRAZIER LIFE SCIENCES VIII, L.P. |
|
1,484,115 | 2022-02-11 | 3 |
GOLD MITCHELL EXECUTIVE CHAIRMAN AND CEO |
|
215,000 | 2022-01-04 | 3 |
RICKEY JAMES PAUL SENIOR VP AND CFO |
|
112,500 | 2022-01-04 | 2 |
PENG STANFORD L SEE REMARKS |
|
215,000 | 2022-01-04 | 1 |
|
10,000 | 2022-01-03 | 4 | |
|
10,000 | 2022-01-03 | 3 | |
|
10,000 | 2022-01-03 | 2 | |
|
10,000 | 2022-01-03 | 2 | |
|
10,000 | 2022-01-03 | 3 | |
|
4,081,592 | 2021-09-17 | 1 | |
|
4,708,288 | 2021-09-17 | 1 | |
|
2,600,980 | 2021-09-17 | 1 | |
|
4,708,288 | 2021-09-17 | 1 | |
GOLDBERG ZELANNA CHIEF MEDICAL OFFICER |
|
0 | 2021-06-01 | 0 |
|
0 | 2021-01-04 | 0 | |
|
3,070,955 | 2020-12-28 | 1 | |
|
0 | 2020-01-02 | 0 | |
|
No longer subject to file | 2019-02-08 | 0 | |
LITTON MARK JAMES SEE REMARKS |
|
0 | 2019-02-06 | 0 |
FRAZIER LIFE SCIENCES VIII, L.P. |
|
2,716,701 | 2019-01-18 | 0 |
|
0 | 2017-07-24 | 0 | |
BIOTECHNOLOGY VALUE FUND II LP |
|
2,028,158 | 2017-06-20 | 0 |
TROHA JANICE EXEC VICE PRESIDENT / COO |
|
10,000 | 2017-05-05 | 0 |
CARRUTHERS R MICHAEL INTERIM PRESIDENT / CFO |
|
0 | 2017-01-12 | 0 |
RODMAN DAVID MALCOM EXEC VICE PRESIDENT AND CMO |
|
11,368 | 2017-01-03 | 0 |
|
0 | 2016-11-01 | 0 | |
|
0 | 2016-09-12 | 0 | |
|
0 | 2016-09-12 | 0 | |
|
0 | 2016-09-12 | 0 | |
|
0 | 2016-09-12 | 0 | |
CONGLETON JON PRESIDENT AND CEO |
|
0 | 2016-09-12 | 0 |
|
0 | 2015-09-11 | 0 | |
SHOEMAKER STEVEN VP CLINICAL R&D |
|
0 | 2015-09-11 | 0 |
GABRIEL SHERIF VICE PRESIDENT RESEARCH |
|
0 | 2015-09-11 | 0 |
DEERFIELD SPECIAL SITUATIONS FUND, L.P. DEERFIELD PRIVATE DESIGN FUND L P DEERFIELD PRIVATE DESIGN FUND II, L.P. |
|
3,732,412 | 2015-06-23 | 0 |
|
No longer subject to file | 2015-06-22 | 0 | |
|
No longer subject to file | 2015-06-22 | 0 | |
|
No longer subject to file | 2015-06-22 | 0 | |
|
1,557,228 | 2015-06-22 | 0 | |
|
No longer subject to file | 2015-06-19 | 0 | |
DEERFIELD PRIVATE DESIGN FUND L P DEERFIELD PRIVATE DESIGN INTERNATIONAL, L.P. DEERFIELD PRIVATE DESIGN FUND II, L.P. |
|
404,022 | 2015-06-16 | 0 |
|
650,915 | 2015-06-16 | 0 | |
|
501,828 | 2011-03-14 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No current insider transactions |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
ALPINE IMMUNE SCIENCES INC ALPN | 2022-06-24 22:15:03 UTC | -1.709 | 3.279 | 100000 |
ALPINE IMMUNE SCIENCES INC ALPN | 2022-06-24 21:45:03 UTC | -1.709 | 3.279 | 100000 |
ALPINE IMMUNE SCIENCES INC ALPN | 2022-06-24 21:15:04 UTC | -1.709 | 3.279 | 100000 |
ALPINE IMMUNE SCIENCES INC ALPN | 2022-06-24 20:45:03 UTC | -2.1138 | 3.6838 | 100000 |
ALPINE IMMUNE SCIENCES INC ALPN | 2022-06-24 20:15:03 UTC | -2.1138 | 3.6838 | 100000 |
ALPINE IMMUNE SCIENCES INC ALPN | 2022-06-24 19:45:03 UTC | -2.1138 | 3.6838 | 100000 |
ALPINE IMMUNE SCIENCES INC ALPN | 2022-06-24 19:15:03 UTC | -2.1138 | 3.6838 | 100000 |
ALPINE IMMUNE SCIENCES INC ALPN | 2022-06-24 18:45:03 UTC | -1.8548 | 3.4248 | 100000 |
ALPINE IMMUNE SCIENCES INC ALPN | 2022-06-24 18:15:04 UTC | -1.8548 | 3.4248 | 100000 |
ALPINE IMMUNE SCIENCES INC ALPN | 2022-06-24 17:45:03 UTC | -1.8548 | 3.4248 | 100000 |
ALPINE IMMUNE SCIENCES INC ALPN | 2022-06-24 17:15:03 UTC | -1.8548 | 3.4248 | 100000 |
ALPINE IMMUNE SCIENCES INC ALPN | 2022-06-24 16:45:03 UTC | -1.8453 | 3.4153 | 100000 |
ALPINE IMMUNE SCIENCES INC ALPN | 2022-06-24 16:15:03 UTC | -1.8453 | 3.4153 | 100000 |
ALPINE IMMUNE SCIENCES INC ALPN | 2022-06-24 15:45:03 UTC | -1.8453 | 3.4153 | 100000 |
ALPINE IMMUNE SCIENCES INC ALPN | 2022-06-24 15:15:03 UTC | -1.8453 | 3.4153 | 100000 |
ALPINE IMMUNE SCIENCES INC ALPN | 2022-06-24 14:45:03 UTC | -1.5682 | 3.1382 | 100000 |
ALPINE IMMUNE SCIENCES INC ALPN | 2022-06-24 14:15:03 UTC | -1.5682 | 3.1382 | 100000 |
ALPINE IMMUNE SCIENCES INC ALPN | 2022-06-24 13:45:03 UTC | -1.5682 | 3.1382 | 100000 |
ALPINE IMMUNE SCIENCES INC ALPN | 2022-06-24 13:15:03 UTC | -1.5682 | 3.1382 | 100000 |
ALPINE IMMUNE SCIENCES INC ALPN | 2022-06-24 12:45:03 UTC | -1.5682 | 3.1382 | 100000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|